Successful Treatment of Lichen Amyloidosis Using a Fixed Combination of Halobetasol-Propionate and Tazarotene Lotion

被引：0
|
作者：
Shoen, Ezra [1 ]
Hou, Angela [1 ]
Zahn, Joseph [1 ]
Friedman, Adam [1 ]
机构：
[1] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA
来源：
JOURNAL OF DRUGS IN DERMATOLOGY | 2021年 / 20卷 / 03期
关键词：
D O I：
10.36849/IDD.2021.5794
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：336 / 337
页数：2
相关论文
共 50 条
  • [31] Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis
    Lebwohl, Mark G.
    Sugarman, Jeffrey L.
    Gold, Linda Stein
    Pariser, David M.
    Lin, Tina
    Pillai, Radhakrishnan
    Martin, Gina
    Harris, Susan
    Israel, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (01) : 282 - 285
  • [32] Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities
    Tyring, Stephen
    Kircik, Leon H.
    Yamauchi, Paul
    Jacobson, Abby
    Lin, Tina
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (04) : 389 - 396
  • [33] Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study
    Lebwohl, M. G.
    Stein Gold, L.
    Papp, K.
    Han, G.
    Pariser, D. M.
    Lin, T.
    Harris, S.
    Jacobson, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (05) : 1152 - 1160
  • [34] Long-term management of moderate-to-severe plaque psoriasis: Maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion
    Gold, L. F. Stein
    Lebwohl, M. G.
    Bhatia, N.
    Lin, T.
    Pillai, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S82 - S82
  • [35] Efficacy, Safety, and Tolerability of Halobetasol Propionate 0.01%-Tazarotene 0.045% Lotion for Moderate to Severe Plaque Psoriasis in the Hispanic Population: Post Hoc Analysis
    Alexis, Andrew F.
    Yamauchi, Paul S.
    Desai, Seemal R.
    Khaselev, Nelly
    Lin, Tina
    CUTIS, 2020, 105 (03): : 150 - +
  • [36] Impact of body mass index (BMI) on the efficacy and safety of halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion in patients with plaque psoriasis
    Lebwohl, Mark G.
    Del Rosso, James Q.
    Alonso-Llamazares, Javier
    Lattouf, Mark
    Jacobson, Abby
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB130 - AB130
  • [37] Real-world treatment outcomes with halobetasol propionate 0.01%/ tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
    Vender, Ronald
    Turchin, Irina
    Lansang, Perla
    Prajapati, Vimal H.
    Legault, Mark
    Barakat, Maxime
    Yeung, Jensen
    JAAD INTERNATIONAL, 2022, 8 : 60 - 63
  • [38] Successful treatment of lichen amyloidosis using capsaicin 8% patch
    Zeidler, C.
    Metze, D.
    Staender, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (07) : 1236 - 1238
  • [39] THE COST-EFFECTIVENESS OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: A CANADIAN ANALYSIS
    Lakzadeh, P.
    Lozano-Ortega, G.
    Gaudet, V
    Johnston, K.
    Barbeau, M.
    VALUE IN HEALTH, 2019, 22 : S363 - S364
  • [40] THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: A NETWORK META-ANALYSIS
    Lozano-Ortega, G.
    Rogula, B.
    Gaudet, V
    Mickle, A.
    Johnston, K.
    Barbeau, M.
    VALUE IN HEALTH, 2019, 22 : S363 - S363
12345